Prof Wenxin Wang and his team of EB researchers received funding from both Debra and the Health Research Board to develop a wound dressing that may have the potential to heal EB wounds and also ease the pain associated with chronic wounds. This wound dressing will be designed to be easily removable so as to not cause any more damage to already fragile EB skin. The dressing will aim to treat EB wounds by mimicking the skin’s natural environment in order to harness collagen production while also delivering a slow release of painkillers to the wound site to minimise the pain associated with these wounds.
Prof Wenxin Wang is a Skin Research and Wound Healing, a Science Foundation Ireland (SFI) Principal Investigator at the Charles Institute of Dermatology, School of Medicine, University College Dublin (UCD), and a member of UCD Academic Council. He won the highly prestigious “Young Scientist Prize in Regenerative Medicine” in 2010 at TERMIS-EU conference, the “SFI Principal Investigator award” in 2011 and the DEBRA Award for Excellent EB Patient Service in 2014, which highlight his work ethic and achievements. Prof. Wang’s scientific interests are in the areas of biomaterials, stem cell and gene therapy for the treatments of skin wounds, cartilage/bone regeneration, dental tissue regeneration, tissue sealant/adhesive. His scientific contribution and achievements have been recognized both nationally and internationally including over 230 peer-reviewed scientific journal papers, 5 book chapters, 34 patents, 164 conference abstracts and presentations, and 117 invited lectures and keynote presentations.
Since 2009 he has graduated 19 PhD students and mentored over 25 postdoctoral researchers. His achievements have gained the increased interest in the wider public community with publicity media activities (56 times in TV Documentary, Videos and Newspapers), for example in RTE, ‘The Sunday Times’, ‘The Irish Times’, ‘Science Daily’ and ‘Chemistry World’. He has been awarded significant funding (ca. 11.87 million Euros) from different sources, e.g., SFI, Health Research Board (HRB), Irish Research Council (IRC), Enterprise Ireland (EI) and European Union (EU-FP7 & EU Horizon 2020) to support his research activities. Prof. Wang has acted as the symposium convener and chair, the member of organizing committees and the member of the conference advisory board for 33 international conferences and has been selected as an expert reviewer and panel member by 27 international research councils and funding bodies. As the founder, Prof Wang has launched 3 companies – Vornia Ltd (www.vornia.com, acquired by Ashland – a Fortune500 US company in Jan. 2018, renamed as Ashland Specialties Ireland), Blafar Ltd. (www.blafar.com), and Branca Bunús Ltd. (www.brancabunus.com). There three companies currently hire 21 employees in Ireland. Furthermore, he has 30 patents in collaboration with industry partners: Ashland, Amryt Biopharm, Blafar and Branca Bunús, and successfully launched and commercialized 5 newly developed technologies onto the market.
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is an inherited disease affecting the skin. Children born with the disease are called ‘butterfly children’ as their skin is seen to be as delicate and fragile as that of a butterfly’s wings. We propose a research program that will address the significant problem of wound healing and pain management in RDEB patients. The goal of this proposed project is to develop an advanced dressing system for the treatment of RDEB wound, will function not only as a wound healing device but also release painkillers directly onto the skin. The basis of this wound dressing will be a miniature injectable gel device known as collagen-based gel. Collagen is one of the main components of the skin; thus, this gel mimics the properties and microenvironment of normal skin. The gel is loaded with pain killers which will be released from the gel directly into the wounds soothing the pain. The gel can be applied by injection through a syringe or tube to wounds and cover and protect the wound site. The dressing can be easily removed from wound site by simply washing the wound area. Pain can be caused by skin loss, wounds and dressing changes. By applying the pain killer loaded gel dressing, pain killers will be slowly released from the gel in a controlled manner. Thus, painful interventions will be managed by easily applying a gel on wound site. One major outcome from this proposed project will be the development of a new generation of wound dressing in combination with a topical painkiller that is capable of promoting wound healing while reducing pain.
Due in 2025
Prof Wenxin Wang